Aeglea Bio Therapeutics (NASDAQ:AGLE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports.
According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “
AGLE has been the topic of a number of other research reports. Piper Sandler assumed coverage on shares of Aeglea Bio Therapeutics in a research report on Monday, May 4th. They set an “overweight” rating and a $12.00 price objective on the stock. Needham & Company LLC assumed coverage on shares of Aeglea Bio Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $11.00 price objective on the stock. HC Wainwright cut their price objective on shares of Aeglea Bio Therapeutics from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, BidaskClub upgraded shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 17th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $12.31.
AGLE traded up $0.02 during trading hours on Tuesday, hitting $9.18. The company’s stock had a trading volume of 9,473 shares, compared to its average volume of 469,776. The company has a current ratio of 3.17, a quick ratio of 3.17 and a debt-to-equity ratio of 0.11. Aeglea Bio Therapeutics has a 12 month low of $3.50 and a 12 month high of $11.38. The stock has a market cap of $410.70 million, a price-to-earnings ratio of -3.78 and a beta of 2.08. The business’s 50-day moving average price is $8.76 and its 200-day moving average price is $7.26.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.08. On average, analysts forecast that Aeglea Bio Therapeutics will post -1.71 earnings per share for the current year.
In related news, CEO Anthony G. Quinn bought 165,000 shares of the stock in a transaction dated Thursday, April 30th. The stock was purchased at an average cost of $4.75 per share, with a total value of $783,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 13.70% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of AGLE. Marshall Wace North America L.P. purchased a new stake in Aeglea Bio Therapeutics in the fourth quarter worth about $51,000. Tower Research Capital LLC TRC lifted its stake in Aeglea Bio Therapeutics by 414.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,312 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 5,890 shares during the period. Citigroup Inc. lifted its stake in Aeglea Bio Therapeutics by 191.2% in the fourth quarter. Citigroup Inc. now owns 7,610 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 4,997 shares during the period. BNP Paribas Arbitrage SA lifted its stake in Aeglea Bio Therapeutics by 150.4% in the first quarter. BNP Paribas Arbitrage SA now owns 8,073 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 4,849 shares during the period. Finally, Alliancebernstein L.P. purchased a new stake in Aeglea Bio Therapeutics in the first quarter worth about $47,000. 46.09% of the stock is owned by hedge funds and other institutional investors.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Recommended Story: Diversification in Investing
Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.